11 results on '"Dingremont, Claire"'
Search Results
2. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
3. Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
4. Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
5. Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry
6. Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients
7. Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry
8. Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study
9. Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort
10. Risk Factors for Bleeding, Including Platelet Count Threshold, in Newly Diagnosed ITP Patients
11. Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.